FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896575493> ?p ?o ?g. }

• W2896575493 endingPage "e8" @default.
• W2896575493 startingPage "e7" @default.
• W2896575493 abstract "To report our institutional experience utilizing stereotactic body radiation therapy (SBRT) for patients with oligometastatic or oligoprogressive colorectal cancer (CRC). Following institutional review board approval, a retrospective chart review was performed to identify patients with oligometastatic or oligoprogressive CRC who received metastasis-directed SBRT. Patient characteristics, treatment characteristics, and oncologic outcomes were collected. Overall survival (OS) from end of first SBRT and local control (LC) were estimated using Kaplan-Meier methods and cumulative incidences, respectively. A total of 85 patients (31 male, 54 female) and 107 lesions were treated between 2008 and 2017. Median follow-up was 20 months (interquartile range [IQR] 10, 41). Median age was 62 (IQR 53, 70). The primary tumor site was colon (63%) or rectum (37%). Forty-one (48%) patients were diagnosed with metastatic disease at initial disease diagnosis. At metastatic diagnosis, most patients were found to have ≤5 metastatic lesions (93%), with most having involvement of 1 (83%) or 2 (14%) organs. Median time from development of metastasis to SBRT was 30 months (IQR 15, 52). All patients received chemotherapy prior to first SBRT. The majority (84%) of patients received other modalities of metastasis-directed local therapy prior to SBRT, including surgery (66%), ablative procedure (34%), conventional palliative dose radiotherapy (RT) (21%), or embolization (2%). Median lesion size treated with SBRT was 2.2 cm (IQR 1.4, 3.8). Table 1 demonstrates the distribution of lesions, 3-year OS, site-specific treatment information, and 3-year LC outcomes. Variables associated with local recurrence were lower biologically effective dose (assuming an α/β = 10, BEDGy10) (HR 0.89, 95% CI 0.80 – 0.99) and larger lesion size (HR 1.32, 95% CI 1.10 – 1.58), when analyzed as continuous variables at 10 Gy and 1 cm increments, respectively. Three-year LC was 81% for lesions receiving BEDGy10 ≥ 113 (the group median dose) versus 48% for BEDGy10 < 113 (p<0.01). The predominant first site of disease progression was distant metastasis outside of SBRT field (76%). SBRT is an effective means of obtaining long-term local control for patients with oligometastatic CRC, with some patients experiencing long-term survival. Higher SBRT doses were associated with better local control.Abstract SU_2_2015; Table 1OS, Treatment Characteristics, and Local control of CRC Metastasis Treated with SBRTSiteNDose (Gy)# fractionsBEDGy103-year LC3-year OS-85----46% (34% - 59%)All10750 (48, 54)4 (3, 5)113 (100, 151)72% (64% - 82%)-Lung4254 (48, 54)3 (3, 4)151 (105, 151)80% (68% - 93%)-Liver3460 (53, 60)5 (5, 5)132 (127, 151)70% (55% - 89%)-Bone1630 (26, 49)3 (3, 5)63 (60, 96)43% (24% - 79%)-Lymph node1050 (44, 50)5 (5, 5)100 (82, 100)100% (69% - 100%)-Other545 (36, 50)5 (5, 5)86 (61, 100)75% (43% - 100%)-* Continuous variables reported as the median (IQR), survival, and LC reported as percentage (95% CI). Open table in a new tab" @default.
• W2896575493 created "2018-10-26" @default.
• W2896575493 creator A5002036484 @default.
• W2896575493 creator A5018405630 @default.
• W2896575493 creator A5023410987 @default.
• W2896575493 creator A5026059969 @default.
• W2896575493 creator A5033323953 @default.
• W2896575493 creator A5044480992 @default.
• W2896575493 creator A5046426146 @default.
• W2896575493 creator A5056662009 @default.
• W2896575493 creator A5060052072 @default.
• W2896575493 creator A5071942279 @default.
• W2896575493 creator A5074277192 @default.
• W2896575493 creator A5076358141 @default.
• W2896575493 creator A5079400879 @default.
• W2896575493 creator A5082478466 @default.
• W2896575493 creator A5083596379 @default.
• W2896575493 creator A5083871900 @default.
• W2896575493 creator A5088854603 @default.
• W2896575493 date "2018-11-01" @default.
• W2896575493 modified "2023-09-27" @default.
• W2896575493 title "Metastasis-Directed Stereotactic Body Radiation Therapy for Oligometastatic Colorectal Cancer: A Single Institution Experience" @default.
• W2896575493 doi "https://doi.org/10.1016/j.ijrobp.2018.07.209" @default.
• W2896575493 hasPublicationYear "2018" @default.
• W2896575493 type Work @default.
• W2896575493 sameAs 2896575493 @default.
• W2896575493 citedByCount "0" @default.
• W2896575493 crossrefType "journal-article" @default.
• W2896575493 hasAuthorship W2896575493A5002036484 @default.
• W2896575493 hasAuthorship W2896575493A5018405630 @default.
• W2896575493 hasAuthorship W2896575493A5023410987 @default.
• W2896575493 hasAuthorship W2896575493A5026059969 @default.
• W2896575493 hasAuthorship W2896575493A5033323953 @default.
• W2896575493 hasAuthorship W2896575493A5044480992 @default.
• W2896575493 hasAuthorship W2896575493A5046426146 @default.
• W2896575493 hasAuthorship W2896575493A5056662009 @default.
• W2896575493 hasAuthorship W2896575493A5060052072 @default.
• W2896575493 hasAuthorship W2896575493A5071942279 @default.
• W2896575493 hasAuthorship W2896575493A5074277192 @default.
• W2896575493 hasAuthorship W2896575493A5076358141 @default.
• W2896575493 hasAuthorship W2896575493A5079400879 @default.
• W2896575493 hasAuthorship W2896575493A5082478466 @default.
• W2896575493 hasAuthorship W2896575493A5083596379 @default.
• W2896575493 hasAuthorship W2896575493A5083871900 @default.
• W2896575493 hasAuthorship W2896575493A5088854603 @default.
• W2896575493 hasConcept C119060515 @default.
• W2896575493 hasConcept C121608353 @default.
• W2896575493 hasConcept C126322002 @default.
• W2896575493 hasConcept C126838900 @default.
• W2896575493 hasConcept C141071460 @default.
• W2896575493 hasConcept C167135981 @default.
• W2896575493 hasConcept C2777106319 @default.
• W2896575493 hasConcept C2779013556 @default.
• W2896575493 hasConcept C2780283643 @default.
• W2896575493 hasConcept C2780387249 @default.
• W2896575493 hasConcept C2781074409 @default.
• W2896575493 hasConcept C509974204 @default.
• W2896575493 hasConcept C526805850 @default.
• W2896575493 hasConcept C71924100 @default.
• W2896575493 hasConceptScore W2896575493C119060515 @default.
• W2896575493 hasConceptScore W2896575493C121608353 @default.
• W2896575493 hasConceptScore W2896575493C126322002 @default.
• W2896575493 hasConceptScore W2896575493C126838900 @default.
• W2896575493 hasConceptScore W2896575493C141071460 @default.
• W2896575493 hasConceptScore W2896575493C167135981 @default.
• W2896575493 hasConceptScore W2896575493C2777106319 @default.
• W2896575493 hasConceptScore W2896575493C2779013556 @default.
• W2896575493 hasConceptScore W2896575493C2780283643 @default.
• W2896575493 hasConceptScore W2896575493C2780387249 @default.
• W2896575493 hasConceptScore W2896575493C2781074409 @default.
• W2896575493 hasConceptScore W2896575493C509974204 @default.
• W2896575493 hasConceptScore W2896575493C526805850 @default.
• W2896575493 hasConceptScore W2896575493C71924100 @default.
• W2896575493 hasIssue "3" @default.
• W2896575493 hasLocation W28965754931 @default.
• W2896575493 hasOpenAccess W2896575493 @default.
• W2896575493 hasPrimaryLocation W28965754931 @default.
• W2896575493 hasRelatedWork W127885312 @default.
• W2896575493 hasRelatedWork W1970423756 @default.
• W2896575493 hasRelatedWork W2135221496 @default.
• W2896575493 hasRelatedWork W2150621467 @default.
• W2896575493 hasRelatedWork W2274368981 @default.
• W2896575493 hasRelatedWork W2327843085 @default.
• W2896575493 hasRelatedWork W3003904233 @default.
• W2896575493 hasRelatedWork W3041376170 @default.
• W2896575493 hasRelatedWork W3118425896 @default.
• W2896575493 hasRelatedWork W3137876420 @default.
• W2896575493 hasVolume "102" @default.
• W2896575493 isParatext "false" @default.
• W2896575493 isRetracted "false" @default.
• W2896575493 magId "2896575493" @default.
• W2896575493 workType "article" @default.